RecruitingNot ApplicableNCT04783441
Use of CGM in Kidney Transplant Recipients
Continuous Glucose Monitoring (CGM) to Improve Glycemic Control in Kidney Transplant Recipients
Sponsor
University of California, Davis
Enrollment
80 participants
Start Date
Jun 29, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
The investigators want to study the impact CGM (continuous glucose monitoring) has on patients glycemic control as determined by time in range (TIR 70-180 mg/dL) in the Diabetic Kidney Transplant population.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Age 18 or above
- Received a kidney transplant within the past year with functioning kidney (eGFR \> 30 mL/min
- Person with Type 2 Diabetes and on insulin
- Access to home wi-fi connection
Exclusion Criteria10
- Person with Type 1 Diabetes
- Patients taking hydroxyurea
- Patient unable to wear the Dexcom G6 device at all times for any reason
- Must be able to test blood glucose with meter 4x a day when on blinded CGM.
- Presence of clinically significant visual or cognitive impairment
- Illiterate
- Prisoners
- Women who are pregnant, who plan to become pregnant during the course of the study, or who are breastfeeding
- Presence of clinically unstable cardiovascular disease
- Active malignancy treatment
Interventions
DEVICEDexcom G6
access to continuous glucose monitoring in the Dexcom G6 arm 24/7
DEVICEDexcom G6 blinded sensor
retrospective access to continuous glucose profile after 10 days of wear
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04783441
Related Trials
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT070644731153 locations
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418115 locations
Project Dulce for Arab Americans With Type 2 Diabetes
NCT055805362 locations
Improving Health Outcomes With Kefir
NCT066952211 location
The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
NCT038787061 location